alendronate has been researched along with Body Weight in 47 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 7.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "Alendronate treatment (25 or 75 mg kg(-1) day(-1)) resulted in a decrease in the colonic damage score and loss of body weight (at 25 mg kg(-1) day(-1) only)." | 7.74 | The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. ( Ballester, I; Daddaoua, A; López-Posadas, R; Martínez-Augustin, O; Nieto, A; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A, 2007) |
| "Osteopenia is a serious medical complication of anorexia nervosa, with no known effective treatment." | 6.71 | Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. ( Carey, D; Golden, NH; Hertz, S; Iglesias, EA; Jacobson, MS; Meyer, W; Schebendach, J; Shenker, IR, 2005) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 5.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "5 μg/kg body weight/day), ovariectomized practicing moderate exercise training, ovariectomized estradiol-treated and practiced a moderate exercise training, and ovariectomized alendronate-treated (OVX + Alen) (OVX + Alen rats were treated orally with alendronate 3 mg/kg body weight/week) groups." | 4.31 | The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats. ( Abdelfattah Abulfadle, K; Mohammed, NA; Osama Mohammed, H; Refaat Abdelkader Atia, R; Saad Ramadan, R, 2023) |
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 3.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| "Alendronate treatment (25 or 75 mg kg(-1) day(-1)) resulted in a decrease in the colonic damage score and loss of body weight (at 25 mg kg(-1) day(-1) only)." | 3.74 | The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. ( Ballester, I; Daddaoua, A; López-Posadas, R; Martínez-Augustin, O; Nieto, A; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A, 2007) |
| "Osteopenia is a serious medical complication of anorexia nervosa, with no known effective treatment." | 2.71 | Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. ( Carey, D; Golden, NH; Hertz, S; Iglesias, EA; Jacobson, MS; Meyer, W; Schebendach, J; Shenker, IR, 2005) |
| "Osteoporosis is defined by loss of bone mass and deteriorated bone microarchitecture." | 1.72 | Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model. ( Amorim, T; Bastos, AR; Canadas, RF; Carrillo, AE; Correlo, VM; Fernandes, EM; Freitas, L; Gkiata, P; Koutedakis, Y; Kydonaki, EK; Marques, F; Ntina, G; Oliveira, JM; Pinto, R; Reguengo, H; Reis, RL; Simón, CR; Vliora, M, 2022) |
| " Long-term use of bisphosphonates prevented reductions in BMI and body weight, usually observed in elderly women." | 1.48 | Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women. ( Inoue, S; Kuroda, T; Shiraki, M; Tanaka, S; Uenishi, K; Urano, F; Urano, T, 2018) |
| "Atorvastatin (ATV) has bone anabolic properties, and alendronate (ALD) is an important antiresorptive drug." | 1.40 | Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats. ( Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM, 2014) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 1.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "Alendronate (ALN) has been reported to increase bone mass by suppressing bone resorption mainly by inducing apoptosis of osteoclasts." | 1.38 | Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. ( Endo, K; Mihara, M; Sakai, S; Shiraishi, A; Takeda, S, 2012) |
| "Bone neoplasms, such as osteosarcoma, exhibit a propensity for systemic metastases resulting in adverse clinical outcome." | 1.37 | Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. ( Benayoun, L; Kopeček, J; Kopečková, P; Pan, H; Satchi-Fainaro, R; Segal, E; Shaked, Y, 2011) |
| " In conclusion, the anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status of bone in OVX mice." | 1.35 | The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. ( Mori, T; Moridera, K; Nakamura, T; Sakai, A; Tanaka, S; Yamane, H, 2009) |
| "ALN suppressed trabecular bone resorption and endocortical bone erosion and formation and increased periosteal bone formation, while ALF increased the number of osteoblasts and suppressed trabecular bone resorption and markedly increased periosteal and endocortical bone formation." | 1.35 | Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. ( Iwamoto, J; K Yeh, J; Matsumoto, H; Sato, Y; Takeda, T, 2008) |
| " Twenty-four male Wistar rats at two months of age were castrated or sham-operated to evaluate the effects of long-term administration (six months) of sodium alendronate at a dose of 1 mg/kg/day." | 1.33 | Effect of alendronate administration on bone mineral density and bone strength in castrated rats. ( Broulik, PD; Rosenkrancová, J; Růzicka, P; Sedlácek, R, 2005) |
| "This indicates that osteopenia is not directly related to neuropathic pain behaviors." | 1.33 | Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb. ( Boulet, JM; Bunton, TE; Sellers, R; Walker, K; Whiteside, GT, 2006) |
| " The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described." | 1.31 | Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. ( Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000) |
| "Alendronate treatment prevented a decrease in bone mineral density and maintained bone mechanical properties after ovariectomy without impairment of bone mineralization in aged rats." | 1.31 | Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. ( Aldini, NN; Carpi, A; Fini, M; Giardino, R; Giavaresi, G; Gnudi, S; Rocca, M, 2001) |
| "Alendronate treatment by itself decreased osteocalcin by day 28 and resulted in a marginal decrease in serum total calcium on day 14." | 1.30 | Alendronate prevents cyclosporin A-induced osteopenia in the rat. ( Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z, 1997) |
| "The alendronate-treated group did not show significant alteration of the breaking load or the cross-sectional shape of the femoral midshaft." | 1.30 | Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. ( Azuma, Y; Kanatani, H; Kiyoki, M; Komoriya, K; Ohta, T; Oue, Y, 1998) |
| "Bone loss associated with postmenopausal osteoporosis can be reduced by treatment with antiresorptive agents such as estrogen or bisphosphonates." | 1.29 | Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. ( Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE, 1996) |
| "Alendronate was administered sc in doses of 0." | 1.28 | The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. ( Quartuccio, HA; Seedor, JG; Thompson, DD, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (14.89) | 18.2507 |
| 2000's | 21 (44.68) | 29.6817 |
| 2010's | 17 (36.17) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelfattah Abulfadle, K | 1 |
| Refaat Abdelkader Atia, R | 1 |
| Osama Mohammed, H | 1 |
| Saad Ramadan, R | 1 |
| Mohammed, NA | 1 |
| Kydonaki, EK | 1 |
| Freitas, L | 1 |
| Reguengo, H | 1 |
| Simón, CR | 1 |
| Bastos, AR | 1 |
| Fernandes, EM | 1 |
| Canadas, RF | 1 |
| Oliveira, JM | 1 |
| Correlo, VM | 1 |
| Reis, RL | 1 |
| Vliora, M | 1 |
| Gkiata, P | 1 |
| Koutedakis, Y | 1 |
| Ntina, G | 1 |
| Pinto, R | 1 |
| Carrillo, AE | 1 |
| Marques, F | 1 |
| Amorim, T | 1 |
| Urano, T | 1 |
| Shiraki, M | 1 |
| Kuroda, T | 1 |
| Tanaka, S | 2 |
| Urano, F | 1 |
| Uenishi, K | 1 |
| Inoue, S | 1 |
| Oršolić, N | 1 |
| Nemrava, J | 1 |
| Jeleč, Ž | 1 |
| Kukolj, M | 1 |
| Odeh, D | 1 |
| Terzić, S | 1 |
| Fureš, R | 1 |
| Bagatin, T | 1 |
| Bagatin, D | 1 |
| Zhao, J | 1 |
| Li, Y | 2 |
| Zhang, H | 1 |
| Shi, D | 1 |
| Li, Q | 1 |
| Meng, Y | 1 |
| Zuo, L | 1 |
| Beattie, JR | 1 |
| Sophocleous, A | 1 |
| Caraher, MC | 1 |
| O'Driscoll, O | 1 |
| Cummins, NM | 1 |
| Bell, SEJ | 1 |
| Towler, M | 1 |
| Rahimnejad Yazdi, A | 1 |
| Ralston, SH | 1 |
| Idris, AI | 1 |
| Swenson, ED | 1 |
| Hansen, KE | 1 |
| Jones, AN | 1 |
| Li, Z | 1 |
| Baltz-Ward, B | 1 |
| Schuna, AA | 1 |
| Elliott, ME | 1 |
| Goes, P | 1 |
| Melo, IM | 1 |
| Silva, LM | 1 |
| Benevides, NM | 1 |
| Alencar, NM | 1 |
| Ribeiro, RA | 1 |
| Lima, V | 1 |
| Siebelt, M | 1 |
| Waarsing, JH | 1 |
| Groen, HC | 1 |
| Müller, C | 1 |
| Koelewijn, SJ | 1 |
| de Blois, E | 1 |
| Verhaar, JA | 1 |
| de Jong, M | 1 |
| Weinans, H | 1 |
| Huh, JE | 1 |
| Kim, SJ | 1 |
| Kang, JW | 1 |
| Nam, DW | 1 |
| Choi, DY | 1 |
| Park, DS | 1 |
| Lee, JD | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Mohamed, MT | 1 |
| Abuelezz, SA | 1 |
| Atalla, SS | 1 |
| El Aziz, LFA | 1 |
| Gorge, SS | 1 |
| Iwamoto, J | 2 |
| Matsumoto, H | 2 |
| Takeda, T | 2 |
| Sato, Y | 2 |
| Xu, E | 1 |
| Yeh, JK | 1 |
| Shomali, T | 1 |
| Rezaian, M | 1 |
| Rassouli, A | 1 |
| Asadi, F | 1 |
| Yamane, H | 1 |
| Sakai, A | 2 |
| Mori, T | 1 |
| Moridera, K | 1 |
| Nakamura, T | 2 |
| Sasaki, H | 1 |
| Miyakoshi, N | 1 |
| Kasukawa, Y | 1 |
| Maekawa, S | 1 |
| Noguchi, H | 1 |
| Kamo, K | 1 |
| Shimada, Y | 1 |
| Segal, E | 1 |
| Pan, H | 1 |
| Benayoun, L | 1 |
| Kopečková, P | 1 |
| Shaked, Y | 1 |
| Kopeček, J | 1 |
| Satchi-Fainaro, R | 1 |
| Swift, JM | 1 |
| Swift, SN | 1 |
| Nilsson, MI | 1 |
| Hogan, HA | 1 |
| Bouse, SD | 1 |
| Bloomfield, SA | 1 |
| Schafer, AL | 1 |
| Sellmeyer, DE | 1 |
| Schwartz, AV | 1 |
| Rosen, CJ | 1 |
| Vittinghoff, E | 1 |
| Palermo, L | 1 |
| Bilezikian, JP | 1 |
| Shoback, DM | 1 |
| Black, DM | 1 |
| Chen, B | 1 |
| Xie, D | 1 |
| Yang, X | 1 |
| Sakai, S | 1 |
| Endo, K | 1 |
| Takeda, S | 1 |
| Mihara, M | 1 |
| Shiraishi, A | 2 |
| Sung, MJ | 1 |
| Davaatseren, M | 1 |
| Hur, HJ | 1 |
| Kim, HJ | 1 |
| Ryu, SY | 1 |
| Choi, YH | 1 |
| Cha, MR | 1 |
| Kwon, DY | 1 |
| Kobayashi, M | 1 |
| Hara, K | 1 |
| Akiyama, Y | 1 |
| Golden, NH | 1 |
| Iglesias, EA | 1 |
| Jacobson, MS | 1 |
| Carey, D | 1 |
| Meyer, W | 1 |
| Schebendach, J | 1 |
| Hertz, S | 1 |
| Shenker, IR | 1 |
| Toro, J | 1 |
| Gentil, MA | 1 |
| García, R | 1 |
| Pérez-Valdivia, MA | 1 |
| García Avellano, E | 1 |
| Algarra, GR | 1 |
| Pereira, P | 1 |
| González-Roncero, F | 1 |
| Mateos, J | 1 |
| Olszynski, WP | 1 |
| Davison, KS | 1 |
| Ioannidis, G | 1 |
| Brown, JP | 1 |
| Hanley, DA | 1 |
| Josse, RG | 1 |
| Murray, TM | 1 |
| Papaioannou, A | 1 |
| Sebaldt, RJ | 1 |
| Tenenhouse, AM | 1 |
| Petrie, A | 1 |
| Goldsmith, CH | 1 |
| Adachi, JD | 1 |
| Broulik, PD | 1 |
| Rosenkrancová, J | 1 |
| Růzicka, P | 1 |
| Sedlácek, R | 1 |
| Greenspan, SL | 1 |
| Beck, TJ | 1 |
| Resnick, NM | 1 |
| Bhattacharya, R | 1 |
| Parker, RA | 1 |
| Ogawa, K | 1 |
| Hori, M | 1 |
| Takao, R | 1 |
| Sakurada, T | 1 |
| Akahoshi, S | 1 |
| Arita, S | 1 |
| Ikeda, S | 1 |
| Morishita, Y | 1 |
| Tsutsumi, H | 1 |
| Ito, M | 1 |
| Whiteside, GT | 1 |
| Boulet, JM | 1 |
| Sellers, R | 1 |
| Bunton, TE | 1 |
| Walker, K | 1 |
| Ornoy, A | 1 |
| Wajnberg, R | 1 |
| Diav-Citrin, O | 1 |
| Ballester, I | 1 |
| Daddaoua, A | 1 |
| López-Posadas, R | 1 |
| Nieto, A | 1 |
| Suárez, MD | 1 |
| Zarzuelo, A | 1 |
| Martínez-Augustin, O | 1 |
| Sánchez de Medina, F | 1 |
| Fuchs, RK | 2 |
| Shea, M | 2 |
| Durski, SL | 1 |
| Winters-Stone, KM | 1 |
| Widrick, J | 1 |
| Snow, CM | 1 |
| K Yeh, J | 1 |
| Phipps, RJ | 2 |
| Burr, DB | 2 |
| Bikle, DD | 1 |
| Morey-Holton, ER | 1 |
| Doty, SB | 1 |
| Currier, PA | 1 |
| Tanner, SJ | 1 |
| Halloran, BP | 1 |
| Peter, CP | 1 |
| Guy, J | 1 |
| Bagdon, W | 1 |
| Kline, WF | 1 |
| Hayes, WC | 1 |
| Frolik, CA | 1 |
| Bryant, HU | 2 |
| Black, EC | 1 |
| Magee, DE | 1 |
| Chandrasekhar, S | 1 |
| Sato, M | 1 |
| Iversen, P | 1 |
| Helterbrand, J | 1 |
| Smietana, F | 1 |
| Bemis, K | 1 |
| Higgs, R | 1 |
| Turner, CH | 1 |
| Owan, I | 1 |
| Takano, Y | 1 |
| Sass, DA | 1 |
| Bowman, AR | 1 |
| Yuan, Z | 1 |
| Ma, Y | 1 |
| Jee, WS | 1 |
| Epstein, S | 1 |
| Azuma, Y | 1 |
| Oue, Y | 1 |
| Kanatani, H | 1 |
| Ohta, T | 1 |
| Kiyoki, M | 1 |
| Komoriya, K | 1 |
| Kaufman, JM | 1 |
| Johnell, O | 1 |
| Abadie, E | 1 |
| Adami, S | 1 |
| Audran, M | 1 |
| Avouac, B | 1 |
| Sedrine, WB | 1 |
| Calvo, G | 1 |
| Devogelaer, JP | 1 |
| Fuchs, V | 1 |
| Kreutz, G | 1 |
| Nilsson, P | 1 |
| Pols, H | 1 |
| Ringe, J | 1 |
| Van Haelst, L | 1 |
| Reginster, JY | 1 |
| Mosekilde, L | 1 |
| Thomsen, JS | 1 |
| Mackey, MS | 1 |
| Giavaresi, G | 1 |
| Fini, M | 1 |
| Gnudi, S | 1 |
| Aldini, NN | 1 |
| Rocca, M | 1 |
| Carpi, A | 1 |
| Giardino, R | 1 |
| Zeni, S | 1 |
| Gomez-Acotto, C | 1 |
| Mautalen, C | 1 |
| Seedor, JG | 1 |
| Quartuccio, HA | 1 |
| Thompson, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Body Weight
| Article | Year |
|---|---|
Background for studies on the treatment of male osteoporosis: state of the art.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Body Height; Body Weight; Bone Density; Fractures | 2000 |
4 trials available for alendronate and Body Weight
| Article | Year |
|---|---|
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).
Topics: Adiponectin; Adiposity; Aged; Aged, 80 and over; Alendronate; Body Weight; Bone Density; Bone Densit | 2011 |
Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alendronate; Amenorrhea; Anorexia Nervosa; Body Weight; Bone Density; Bone Diseas | 2005 |
Alendronate in kidney transplant patients: a single-center experience.
Topics: Alendronate; Body Weight; Bone Density; Calcium; Female; Humans; Lumbar Vertebrae; Male; Menopause; | 2005 |
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
Topics: Aged; Aging; Alendronate; Body Weight; Bone and Bones; Bone Density; Densitometry; Diphosphonates; D | 2005 |
42 other studies available for alendronate and Body Weight
| Article | Year |
|---|---|
The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats.
Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone Density; Estradiol; Female; Humans; Osteopontin; | 2023 |
Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model.
Topics: Alendronate; Animals; Body Weight; Bone Density; Cattle; Colostrum; Dietary Supplements; Female; Hum | 2022 |
Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.
Topics: Aged; Alendronate; Asian People; Biomarkers; Body Composition; Body Mass Index; Body Weight; Bone De | 2018 |
The Beneficial Effect of Proanthocyanidins and Icariin on Biochemical Markers of Bone Turnover in Rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2018 |
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
Topics: Alendronate; Animals; Blood Glucose; Body Weight; Bone Density; Female; Femur; Glucocorticoids; Lipi | 2019 |
Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Disease Models, A | 2019 |
Characteristics associated with bone mineral density responses to alendronate in men.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Body Weight; Bone Density; Bone Density Cons | 2013 |
Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alanine Transaminase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Anima | 2014 |
Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Resorption; Cartilage, Articular; Disease Pr | 2014 |
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Astragalus propinquus; Body Weight; Bone Density; Bone Resorption; Cinnamomum | 2015 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
The anti-osteoporotic and anti-atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy.
Topics: Alendronate; Alkaline Phosphatase; Animals; Atherosclerosis; Body Weight; Bone and Bones; Bone Densi | 2017 |
Effects of alendronate and alfacalcidol on the femoral bone mass and bone strength in orchidectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Femur; Hydroxycholecalciferols; Male; Orchiectomy; | 2008 |
Effect of eicosapentaenoic acid on bone changes due to methylprednisolone in rats.
Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density Conservation Agents; Bon | 2009 |
The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Topics: Alendronate; Animals; Apoptosis; Body Weight; Bone Density; Bone Remodeling; Cathepsin K; Cathepsins | 2009 |
Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Density Conservation | 2010 |
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Bone | 2011 |
Cancellous bone formation response to simulated resistance training during disuse is blunted by concurrent alendronate treatment.
Topics: Acid Phosphatase; Adipocytes; Alendronate; Animals; Apoptosis; Body Weight; Bone and Bones; Cell Cou | 2011 |
Low-magnitude high-frequency loading via whole body vibration enhances bone-implant osseointegration in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Density Conservation | 2012 |
Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Body Weight; Bon | 2012 |
Antiosteoporotic activity of Saururus chinensis extract in ovariectomized rats.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Body Weight; Bone Density; Bone | 2012 |
Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet.
Topics: Alendronate; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Calcitriol; C | 2004 |
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
Topics: Alendronate; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Aci | 2006 |
Effect of alendronate administration on bone mineral density and bone strength in castrated rats.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Body Weight; | 2005 |
Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Density; Calcitonin; Compressive Strength; D | 2005 |
Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.
Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Alendronate; Animals; Body Weight; Bone and Bones; B | 2005 |
Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2006 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |
The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats.
Topics: Administration, Oral; Alendronate; Animals; Anti-Inflammatory Agents; Body Weight; Bone Density Cons | 2007 |
Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Compressive Stren | 2007 |
Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study.
Topics: Alendronate; Animals; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone | 2008 |
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2008 |
Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.
Topics: Alendronate; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcific | 1994 |
Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
Topics: Administration, Oral; Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Ca | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Mo | 1996 |
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Estrogens; Female; Ovariectomy; Piperidines; Ralo | 1996 |
Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabo | 1997 |
Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Diphosphon | 1998 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; | 2000 |
Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; | 2001 |
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Ra | 2001 |
The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Resorption; Diphosphonates; Female; Ovariect | 1991 |